SILENCE THERAP. SP.ADR/1 Market Cap ($245.62 Million)
Market Cap & Net Worth: SILENCE THERAP. SP.ADR/1 (XRP2)
SILENCE THERAP. SP.ADR/1 market cap. SILENCE THERAP. SP.ADR/1 (F:XRP2) has a market capitalization of $245.62 Million (€210.09 Million) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #15521 globally and #1513 in its home market, demonstrating a 40.56% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SILENCE THERAP. SP.ADR/1's stock price €7.00 by its total outstanding shares 47233949 (47.23 Million). Also see cash efficiency ratio of SILENCE THERAP. SP.ADR/1 for how efficiently the company converts equity into cash flow.
SILENCE THERAP. SP.ADR/1 Market Cap History (2020–2026)
SILENCE THERAP. SP.ADR/1 market cap history from 2020 to 2026. Data shows change from $855.93 Million to $966.38 Million (-13.51% CAGR). Check XRP2 stock price and chart for real-time trading data and today's change.
SILENCE THERAP. SP.ADR/1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SILENCE THERAP. SP.ADR/1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore XRP2 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
503.81x
SILENCE THERAP. SP.ADR/1's market cap is 503.81 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.18 Billion | $16.76 Million | -$53.19 Million | 70.53x | N/A |
| 2022 | $784.14 Million | $21.66 Million | -$50.33 Million | 36.21x | N/A |
| 2023 | $839.37 Million | $31.64 Million | -$54.23 Million | 26.53x | N/A |
| 2024 | $361.70 Million | $43.26 Million | -$45.31 Million | 8.36x | N/A |
| 2025 | $281.63 Million | $559.00K | -$88.61 Million | 503.81x | N/A |
Competitor Companies of XRP2 by Market Capitalization
Companies near SILENCE THERAP. SP.ADR/1 in the global market cap rankings as of November 3, 2026. Also see balance sheet size of SILENCE THERAP. SP.ADR/1 for a full breakdown of the balance sheet.
Key companies related to SILENCE THERAP. SP.ADR/1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of SILENCE THERAP. SP.ADR/1 (2020–2026)
Market capitalization of SILENCE THERAP. SP.ADR/1 from 2020 to today. Between 2020 and today, SILENCE THERAP. SP.ADR/1's market cap moved from $855.93 Million to $ 966.38 Million, with a yearly change of -13.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €966.38 Million | +243.14% |
| 2025 | €281.63 Million | -22.14% |
| 2024 | €361.70 Million | -56.91% |
| 2023 | €839.37 Million | +7.04% |
| 2022 | €784.14 Million | -33.64% |
| 2021 | €1.18 Billion | +38.06% |
| 2020 | €855.93 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of SILENCE THERAP. SP.ADR/1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $245.62 Million USD |
| MoneyControl | $245.62 Million USD |
| MarketWatch | $245.62 Million USD |
| marketcap.company | $245.62 Million USD |
| Reuters | $245.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SILENCE THERAP. SP.ADR/1
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated … Read more